Krystal Biotech - KRYS Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Krystal Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KRYS shares.
View KRYS analyst ratings or view top-rated stocks.

4 equities research analysts have issued twelve-month price targets for Krystal Biotech's shares. Their KRYS share price forecasts range from $101.00 to $133.00. On average, they predict the company's share price to reach $119.25 in the next year. This suggests a possible upside of 53.1% from the stock's current price.
View analysts price targets for KRYS or view top-rated stocks among Wall Street analysts.

Krystal Biotech's stock was trading at $79.22 at the beginning of 2023. Since then, KRYS stock has decreased by 1.7% and is now trading at $77.89.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our KRYS earnings forecast.

Krystal Biotech, Inc. (NASDAQ:KRYS) released its earnings results on Monday, February, 27th. The company reported ($1.25) earnings per share for the quarter, beating analysts' consensus estimates of ($1.26) by $0.01.

ETFs with the largest weight of Krystal Biotech (NASDAQ:KRYS) stock in their portfolio include Jacob Forward ETF (JFWD), Franklin Genomic Advancements ETF (HELX), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Harbor Disruptive Innovation ETF (INNO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Krystal Biotech investors own include Pfizer (PFE), Allena Pharmaceuticals (ALNA), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), VBI Vaccines (vbiv), Verastem (VSTM), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT) and NVIDIA (NVDA).

(KRYS) raised $30 million in an initial public offering on Wednesday, September 20th 2017. The company issued 3,000,000 shares at $9.00-$11.00 per share. Ladenburg Thalmann served as the underwriter for the IPO.

Krystal Biotech trades on the NASDAQ under the ticker symbol "KRYS."

Krystal Biotech's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.48%), Lord Abbett & CO. LLC (4.96%), Frazier Life Sciences Management L.P. (3.88%), Credit Suisse AG (2.65%), Point72 Asset Management L.P. (2.16%) and First Light Asset Management LLC (1.84%). Insiders that own company stock include Dino A Rossi, Krish S Krishnan and Suma Krishnan.
View institutional ownership trends.

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of KRYS stock can currently be purchased for approximately $77.89.

Krystal Biotech (NASDAQ:KRYS) has a market capitalization of $2.01 billion. The company earns $-139,980,000.00 in net income (profit) each year or ($5.51) on an earnings per share basis.

The company employs 119 workers across the globe.

Krystal Biotech's mailing address is 2100 WHARTON STREET SUITE 701, PITTSBURGH PA, 15203. The official website for the company is www.krystalbio.com. The company can be reached via phone at (412) 586-5830 or via email at arr@lifesciadvisors.com.